Sjogren’s Syndrome Plasma

About Sjogren’s Syndrome Plasma

Sjogren’s Syndrome Plasma for Autoimmune and Autoantibody Research

Sjogren’s Syndrome Plasma is collected from IRB-consented donors clinically diagnosed with Sjogren’s syndrome and processed within one day of collection to preserve labile analytes such as cytokines, proteins and metabolites. Sjogren’s syndrome is a systemic autoimmune disease in which lymphocytic infiltration of the salivary and lacrimal glands produces dryness of the mouth and eyes, accompanied by autoantibody production and a type I interferon-driven inflammatory response. Bulk plasma is available for higher-volume programs.

What Sjogren’s Syndrome Plasma Reveals

• Sjogren’s syndrome is defined serologically by anti-Ro/SSA autoantibodies, directed against Ro52/TRIM21 and Ro60, frequently with anti-La/SSB, ANA and rheumatoid factor. These autoantibodies are a genuine feature of the disease rather than a template phrase, and plasma from characterised donors supports assay development against each specificity.
• Polyclonal B-cell hyperactivity is a hallmark, producing hypergammaglobulinaemia and elevated free light chains. Plasma is the practical matrix for quantifying total and subclass immunoglobulins, free light chains and beta-2 microglobulin as measures of that B-cell drive.
• The B-cell survival factor BAFF and the B-cell chemoattractant CXCL13 are elevated in Sjogren’s syndrome and reflect the ectopic lymphoid organisation seen in affected glands. Both are measurable in plasma and both sit on pathways being targeted therapeutically.
• A type I interferon signature is well documented, and interferon-inducible chemokines such as CXCL10 are measurable in plasma, giving a systemic readout of a pathway central to disease biology.
• Sjogren’s syndrome carries a materially increased risk of B-cell lymphoma, particularly mucosa-associated lymphoid tissue lymphoma of the parotid. Persistently low C4 and cryoglobulinaemia are recognised risk markers, and complement components are best preserved in citrate or EDTA plasma rather than in serum, where clotting consumes them.
• Disease extends well beyond sicca symptoms to fatigue, arthralgia, interstitial lung disease, peripheral neuropathy and cutaneous vasculitis, so plasma from donors annotated by extraglandular involvement supports linking circulating markers to specific systemic domains.

Donor Stratification Available

• Autoantibody profile where documented: anti-Ro/SSA (Ro52 and Ro60), anti-La/SSB, ANA pattern and titre, rheumatoid factor
• Primary Sjogren’s syndrome versus secondary disease with rheumatoid arthritis, SLE or systemic sclerosis
• Disease activity where documented, including ESSDAI, and patient-reported symptom burden by ESSPRI
• Laboratory features where documented: hypergammaglobulinaemia, low C4, cryoglobulinaemia, and labial gland biopsy focus score
• Extraglandular involvement: articular, pulmonary, neurological, cutaneous vasculitis, or renal; and history of lymphoproliferative disease
• Treatment status including hydroxychloroquine, corticosteroid, immunosuppressant or B-cell directed therapy; matched healthy controls available

Product Features

• Research Use Only (RUO)
• Plasma collected from clinically confirmed Sjogren’s syndrome donors
• Processed within one day of collection
• Anticoagulant selection (EDTA, citrate, heparin) available on request
• IRB-approved protocols and informed consent
• Custom aliquot volumes available upon request; volumes reported per lot

De-identified Donor Data

• Verified Sjogren’s syndrome diagnosis
• Demographic data: age, sex assigned at birth, race/ethnicity
• Donor-reported medications, allergies, and comorbidities
• Additional Sjogren’s syndrome-specific metadata available on request

Applications

• Anti-Ro/SSA and anti-La/SSB autoantibody assay development and validation
• BAFF, CXCL13 and B-cell axis biomarker research
• Type I interferon signature and interferon-inducible chemokine profiling
• Immunoglobulin, free light chain and complement quantification
• Lymphoma risk marker research, including low C4 and cryoglobulinaemia
• Plasma proteomics and metabolomics
• Disease activity and treatment-response biomarker discovery
• Therapeutic target validation and pharmacodynamic assay development

Other Sjogren’s Syndrome Specimen Types

• Sjogren’s Syndrome Serum
• Sjogren’s Syndrome Whole Blood
• Sjogren’s Syndrome PBMC
• Sjogren’s Syndrome Leukopak
• Sjogren’s Syndrome Bulk Plasma
• Sjogren’s Syndrome CD19+ B Cells
• Primary Sjogren’s Syndrome Plasma
• Secondary Sjogren’s Syndrome Plasma

Compliance and Quality Assurance

• IRB-approved and HIPAA-compliant protocols
• Electronic informed consent with 21 CFR Part 11 – compliant e-signatures
• Documentation support available for regulatory review

Ordering & Customization

Sjogren’s syndrome plasma is available in standard and custom volumes. For pricing, current availability, or a quote on a stratified donor cohort, email learnmore@sanguinebio.com. For international orders or documentation requirements, please contact us to ensure compatibility with your country’s regulations. To browse other disease states in this specimen type, visit our human plasma page.